Advanced Filters
noise

sarcoidosis Clinical Trials

A listing of sarcoidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 51 clinical trials
S Susanna Kullberg, MD

Sarcoidosis and Immune Cells in Lung, Lymph Nodes and Blood

Background Sarcoidosis is an inflammatory disease, most commonly affecting the lungs and intrathoracic lymph nodes but can affect virtually any organ, sometimes manifesting as life threatening cardiac arrythmias. Some patients resolve spontaneously, whereas others get a chronic disease leading to for instance impaired lung function and cardiac failure. The most …

18 - 90 years of age Both Phase N/A
8 877-596-6699

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant …

18 - 100 years of age Both Phase 3
N Nicole Olszewski

Janus Kinase Inhibition in Sarcoidosis

The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.

18 - 100 years of age Both Phase 2
L Laura Koth, MD

Use of CXCL9 as a Biomarker of Acthar Efficacy

The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

18 - 65 years of age Both Phase 4
F Fleur Dr COHEN-AUBART

Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis

In severe refractory sarcoidosis not responding to conventional immunosuppressive treatment, the third-line tumor necrosis factor (TNF)-alpha inhibitor infliximab is an alternative. Treatment duration is not known, although it has been suggested that relapse rates after withdrawal could be high. We hypothesize that a prolonged course of TNF-alpha would be better …

18 - 100 years of age Both Phase 3
K K Nakasuka, MD

Cardiac Sarcoidosis Randomized Trial

Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in …

18 - 100 years of age Both Phase 3
T Thomas Vandemoortele, MD, MSc

Effect of Needle Size in Diagnostic Yield of EBUS-TBNA in Sarcoidosis and Lymphoma

The guided FNA by endobronchial ultrasound ( Endobronchial Ultrasound guided transbronchial Needle Aspiration or EBUS-TBNA) is a minimally invasive technique with an established role in the staging of lung cancer 1, and in the evaluation of intrathoracic lymph node metastases from extrathoracic primary cancer2 . There is also a role …

18 - 100 years of age Both Phase N/A
J Jose Cerdan

Feasibility & Effect of a Tele-rehabilitation Program in Pulmonary Sarcoidosis Pulmonary Sarcoidosis

Pulmonary sarcoidosis (PS) is defined as a multisystem granulomatous disorder of unknown cause affecting different vital organs, especially the lungs. PS manifest in reduction of pulmonary function. Overall symptoms lead to poor physical conditioning contributing to a vicious cycle of more physical inactivity. Treatment of sarcoidosis is usually limited to …

18 - 100 years of age Both Phase N/A

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis

18 - 80 years of age Both Phase 1/2

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

18 - 100 years of age Both Phase 2

Rewrite in simple language using AI